Pfizer's Problems Go Far Beyond Just Declining COVID Revenue
A lot can change on the stock market in just a few years, and Pfizer (NYSE: PFE) is a great example. At the end of 2021, its shares were trading at around $60, and things were looking great for the COVID-19 vaccine maker. It would go on to hit a record of more than $100 billion in annual revenue in 2022.
Today, however, the stock is below $30 per share. What was once hype and excitement surrounding the stock has now been replaced with fear and concern as investors worry about what the future holds for the business.
Revenue from its COVID-19 products likely won't ever be as strong as it was in 2022. But the problems for Pfizer go even deeper. Here's why.
Source Fool.com
Pfizer Inc. Stock
€25.82
-0.540%
The stock is one of the favorites of our community with 31 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 58.79% compared to the current price of 25.82 € for Pfizer Inc..
